Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab for Relapsing-Remitting Multiple Sclerosis.

× No keyword cloud information.

17 in total

Review 1. [New aspects of immunotherapy in multiple sclerosis].

Authors: K Pape; F Zipp; S Bittner
Journal: Nervenarzt Date: 2018-12 Impact factor: 1.214

Review 2. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors: Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal: Clin Microbiol Rev Date: 2020-06-10 Impact factor: 26.132

Review 3. Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Authors: Joachim Havla; Clemens Warnke; Tobias Derfuss; Ludwig Kappos; Hans-Peter Hartung; Reinhard Hohlfeld
Journal: Dtsch Arztebl Int Date: 2016-12-26 Impact factor: 5.594

Review 4. Infectious Complications of Novel Multiple Sclerosis Therapies.

Authors: S N Levin; T B Kaplan
Journal: Curr Infect Dis Rep Date: 2017-02 Impact factor: 3.725

5. Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.

Authors: Cristian Deana; Daniele Bagatto; Alessandra Battezzi; Davide Pecori; Simone Lorenzut; Francesco Tuniz
Journal: J Neurol Date: 2022-03-30 Impact factor: 6.682

Review 6. Managing Risks with Immune Therapies in Multiple Sclerosis.

Authors: Moritz Förster; Patrick Küry; Orhan Aktas; Clemens Warnke; Joachim Havla; Reinhard Hohlfeld; Jan Mares; Hans-Peter Hartung; David Kremer
Journal: Drug Saf Date: 2019-05 Impact factor: 5.606

7. Treatment of Autoimmune Diseases with Therapeutic Antibodies: Lessons Learned from PID Patients Allow for Stratification of the Infection Risk.

Authors: Joyce J B C van Beers; Jan G M C Damoiseaux
Journal: Methods Mol Biol Date: 2022

Review 8. Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations.

Authors: Jan Dörr; Karl Baum
Journal: Drug Des Devel Ther Date: 2016-10-18 Impact factor: 4.162

Review 9. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.

Authors: Gabriel Pardo; David E Jones
Journal: J Neurol Date: 2017-09-06 Impact factor: 4.849

Review 10. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

Authors: Cristina Guarnera; Placido Bramanti; Emanuela Mazzon
Journal: Ther Clin Risk Manag Date: 2017-07-14 Impact factor: 2.423